Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 221

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Long‐term outcomes after randomization to buprenorphine/naloxone versus methadone in a multi‐site trial

Open access
Hser, Yih‐Ing, Evans, Elizabeth, Huang, David, Weiss, Robert, Saxon, Andrew, Carroll, Kathleen M., Woody, George, Liu, David, Wakim, Paul, Matthews, Abigail G., Hatch‐Maillette, Mary, Jelstrom, Eve, Wiest, Katharina, McLaughlin, Paul, Ling, Walter·2016·Addiction

Abstract

Aims: To compare long‐term outcomes among participants randomized to buprenorphine or methadone. Design, Setting and Participants: Follow‐up was conducted in 2011–14 of 1080 opioid‐dependent participants entering seven opioid treatment programs in the United States between 2006 and 2009 and randomized (within each program) to receive open‐label buprenorphine/naloxone or methadone for up to 24 weeks; 795 participants completed in‐person interviews (~74% follow‐up interview rate) covering on average 4.5 years. Measurements: Outcomes were indicated by mortality and opioid use. Covariates included demographics, site, cocaine use and treatment experiences. Findings: Mortality was not different between the two randomized conditions, with 23 (3.6%) of 630 participants randomized to buprenorphine having died versus 26 (5.8%) of 450 participants randomized to methadone. Opioid use at follow‐up was higher among participants randomized to buprenorphine relative to methadone [42.8 versus 31.7% positive opioid urine specimens, P < 0.01, effect size (h) = 0.23 (0.09, 0.38); 5.8 days versus 4.4 days of past 30‐day heroin use, P < 0.05, effect size (d) = 0.14 (0.00, 0.28)]. Opioid use during the follow‐up period by randomization condition was also significant (F(7,39 600) = 3.16; P < 0.001) due mainly to less treatment participation among participants randomized to buprenorphine than methadone. Less opioid use was associated with both buprenorphine and methadone treatment (relative to no treatment); no difference was found between the two treatments. Individuals who are white or used cocaine at baseline responded better to methadone than to buprenorphine. Conclusions: There are few differences in long‐term outcomes between buprenorphine and methadone treatment for opioid dependence, and treatment with each medication is associated with a strong reduction in opioid use.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/add.13238

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 221

Metadata

Authors
Hser, Y., Evans, E., Huang, D., Weiss, R., Saxon, A., Carroll, K. M., Woody, G., Liu, D., Wakim, P., Matthews, A. G., Hatch‐Maillette, M., Jelstrom, E., Wiest, K., McLaughlin, P., & Ling, W.
Venue
Addiction
Publisher
Wiley
Published
2016-01-13
Volume
111
Issue
4
Pages
695-705
ISSN
  • 0965-2140 (ISSN-L)
  • 1360-0443
OpenAlex
W2173844711
Cited by
221
References
3
FWCI
12.29
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Long‐term outcomes after randomization to buprenorphine/naloxone versus methadone in a multi‐site trial. https://app.cochat.ai/papers/10.1111/add.13238
The paper
Hser, Y., Evans, E., Huang, D., Weiss, R., Saxon, A., Carroll, K. M., Woody, G., Liu, D., Wakim, P., Matthews, A. G., Hatch‐Maillette, M., Jelstrom, E., Wiest, K., McLaughlin, P., & Ling, W. (2016). Long‐term outcomes after randomization to buprenorphine/naloxone versus methadone in a multi‐site trial. Addiction. https://doi.org/10.1111/add.13238

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.